Abstract
In 2010, important research into the systemic autoinflammatory diseases has confirmed and extended the role of IL-1 inhibition in hereditary autoinflammatory disorders, demonstrated a novel treatment for a dangerous complication, and expanded the spectrum of systemic autoinflammatory diseases while further implicating autoinflammation in the pathophysiology of the metabolic syndrome.
MeSH terms
-
Amyloidosis / drug therapy
-
Amyloidosis / etiology
-
Animals
-
Antirheumatic Agents / pharmacology
-
Antirheumatic Agents / therapeutic use*
-
Atherosclerosis / etiology
-
Hereditary Autoinflammatory Diseases / complications
-
Hereditary Autoinflammatory Diseases / drug therapy*
-
Humans
-
Interleukin 1 Receptor Antagonist Protein / pharmacology
-
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
-
Interleukin-1 / antagonists & inhibitors
Substances
-
Antirheumatic Agents
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1